bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 12-17

  Scherr, Douglas S ^a   Vaughan Jr , E Darracott ^a   Wei, John ^a   Chung, Marilda ^a   Felsen, Diane ^a   Allbright, Robert ^a   Knudsen, Beatrice S ^a  

^a NONE

Author keywords

Apoptosis; Prostate; Prostate specific antigen; Radiotherapy; Tumor markers, biological

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT FAILURE;

EID: 0032828118     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00003     Document Type: Article

References (31)

1. Cancer Facts and Figures, 1998. American Cancer Society. Online: http://www.cancer.org/links.html
2. Ennis, R. E. and Peschel, R. E.: Radiation therapy for prostate cancer: long-term results and implications for future advances. Cancer, 72: 2644, 1993.
3. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. J. Amer. Med. Ass., 277: 1445, 1997.
4. Zincke, H., Blute, M. L., Fallen, M. J. and Farrow, G. M.: Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implication for treatment recommendations and disease outcome. J. Urol., 146: 1053, 1991.
5. Myers, R. B. and Grizzle, W. E.: Changes in biomarker expression in the development of prostatic adenocarcinoma. Biotech. Histochem., 72: 86, 1997.
6. Bauer, J. J., Sesterhann, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer. J. Urol., 156: 1511, 1996.
7. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Bauer, J. J.: Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996.
8. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S. and Reed, J. C.: Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Amer. J. Path., 148: 1567, 1996.
9. Woloschak, G. E.: Different pathways for radiation-induced apoptosis. Int. J. Rad. Oncol., 39: 951, 1997.
10. Reed, J. C., Zha, H. G. and Aime-Sempe, C.: Structure-function analysis of bcl-2 family proteins. In: Mechanisms of Lymphocyte Activation and Immune Regulation VI. Edited by S. Gupta and J. J. Cohen. New York: Plenum Press, pp. 99-112, 1996.
11. Kroemer, G.: The proto-oncogene bcl-2 and its role in regulating apoptosis. Nature Med., 3: 614, 1997.
12. Knudson, C. M. and Korsmeyer, S. J.: Bcl-2 and Bax function independently to regulate cell death. Nature Genet., 16: 358, 1997.
13. Vogelstein, B. and Kinzler, K. W.: p53 function and dysfunction. Cell, 70: 523, 1992.
14. Isaacs, J. T.: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251, 1996.
15. Stamey, T. A., Ferrari, M. K. and Schmid, H. P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol., 150: 1856, 1993.
16. Hancock, S. L., Cox, R. S. and Bagshaw, M. A.: Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J. Urol., 154: 1412, 1995.
17. Wallace, D. M., Chisolm, G. D. and Hendry, W. F.: T.N.M. classification for urological tumours (UICC)-1974. Brit. J. Urol., 47: 1, 1975.
18. DeMarzo, A. M., Meeker, A. K., Epstein, J. I. and Coffey, D. S.: Prostate stem cell compartments: Expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells. Amer. J. Path., 153: 911, 1998.
19. Pilepich, M. V., Krall, J. M., al-Saraaf, M., John, M. J., Doggett, R. L., Sause, W. T., Lawton, C. A., Abrams, R. A., Rotman, M. and Rubin, P.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate cancer: a randomized comparative trial of the Radiation Tumor Oncology Group. Urology, 45: 616, 1995.
20. Pound, C. R., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Prostate specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. N. Amer., 24: 395, 1997.
21. Ahmed, M., Sells, S. F. and Venkatasubbarao, K.: Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J. Biol. Chem., 272: 33056, 1997.
22. Critz, F. A., Levinson, K., Williams, W. H., Holladay, D. A. and Holladay, C. T.: The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology, 49: 322, 1997.
23. Schellhammer, P., El-Mahdi, A. M., Wright, G. L., Jr., Kolm, P. and Ragle, R.: Prostate specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology, 42: 13, 1993.
24. Chen, M., Quintans, J., Fuks, Z., Thompson, C., Kufe, D. W. and Weichselbaum, R. R.: Suppression of bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res., 55: 991, 1995.
25. Prendergast, N. J., Atkins, M. R., Schatte, E. C., Paulson, D. F. and Walther, P. J.: P53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated local persistent prostate carcinoma. J. Urol., 155: 1685, 1996.
26. Miller, G. J. and Cygan, J. M.: Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol., 152: 1709, 1994.
27. Shurbaju, M. S., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Path., 26: 106, 1995.
28. Matsushima, H., Kitamura, T., Goto, T., Hosaka, Y., Homma, Y. and Kawabe, K.: Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol., 158: 2278, 1997.
29. Huang, A., Gandour-Edwards, R., Rosenthal, S. A., Siders, D. B., Deitch, A. D. and White, R. W.: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology, 51: 346, 1998.
30. Grignon, D. J., Caplan, R., Sarkar, F. H., Lawton, C. A., Hammond, E. H., Pilepich, M. V., Forman, J. D., Mesic, J., Fu, K. K., Abrams, R. A., Pajak, T. F., Shipley, W. U. and Cox, J. D.: P53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J. Natl. Cancer Inst., 89: 158, 1997.
31. Grossfeld, G. D., Olumi, A. F., Connolly, J. A., Chew, K., Gibney, J., Bhargava, V., Waldman, F. M. and Carroll, P. C.: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in KI-67 labeling index, p53 and bcl-2 immunoreactivity. J. Urol., 159: 1437, 1998.